Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
16.00
Dollar change
-0.59
Percentage change
-3.56
%
Index- P/E- EPS (ttm)- Insider Own61.82% Shs Outstand23.40M Perf Week-1.90%
Market Cap411.52M Forward P/E- EPS next Y-1.57 Insider Trans0.00% Shs Float9.82M Perf Month4.51%
Income- PEG- EPS next Q-0.35 Inst Own12.78% Short Float5.76% Perf Quarter-
Sales- P/S- EPS this Y-4172.22% Inst Trans- Short Ratio5.96 Perf Half Y-
Book/sh-2.94 P/B- EPS next Y14.32% ROA- Short Interest0.57M Perf Year-
Cash/sh4.58 P/C3.49 EPS next 5Y- ROE- 52W Range13.27 - 18.50 Perf YTD3.90%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-13.51% Beta-
Dividend TTM- Quick Ratio19.20 Sales past 5Y0.00% Gross Margin- 52W Low20.57% ATR (14)1.08
Dividend Ex-Date- Current Ratio19.20 EPS Y/Y TTM- Oper. Margin- RSI (14)50.67 Volatility10.16% 6.34%
Employees31 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price28.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q- Payout- Rel Volume0.22 Prev Close16.59
Sales Surprise- EPS Surprise-218.39% Sales Q/Q- EarningsMay 16 AMC Avg Volume94.84K Price16.00
SMA200.83% SMA502.54% SMA2002.54% Trades Volume20,874 Change-3.56%
Date Action Analyst Rating Change Price Target Change
Apr-30-24Initiated Stifel Buy $29
Apr-30-24Initiated RBC Capital Mkts Outperform $30
Apr-30-24Initiated Morgan Stanley Overweight $25
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.